BR112022007705A2 - Método para diagnóstico de doença relacionada ao vírus da leucemia tipo 1 de células t humanas (htlv-1) - Google Patents

Método para diagnóstico de doença relacionada ao vírus da leucemia tipo 1 de células t humanas (htlv-1)

Info

Publication number
BR112022007705A2
BR112022007705A2 BR112022007705A BR112022007705A BR112022007705A2 BR 112022007705 A2 BR112022007705 A2 BR 112022007705A2 BR 112022007705 A BR112022007705 A BR 112022007705A BR 112022007705 A BR112022007705 A BR 112022007705A BR 112022007705 A2 BR112022007705 A2 BR 112022007705A2
Authority
BR
Brazil
Prior art keywords
htlv
human
cell leukemia
virus type
leukemia virus
Prior art date
Application number
BR112022007705A
Other languages
English (en)
Inventor
Yoshihara Yoshiko
Fukushima Takuya
Tanaka Yuetsu
Masuzaki Hiroaki
Karube Kennosuke
Imaizumi Naoki
Original Assignee
Nec Corp
Univ Of The Ryukyus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nec Corp, Univ Of The Ryukyus filed Critical Nec Corp
Publication of BR112022007705A2 publication Critical patent/BR112022007705A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Abstract

MÉTODO PARA DIAGNÓSTICO DE DOENÇA RELACIONADA AO VÍRUS DA LEUCEMIA TIPO 1 DE CÉLULAS T HUMANAS (HTLV-1). Como uma técnica que permite diagnosticar de forma simples e precisa a doença relacionada ao vírus da leucemia de células T humanas tipo 1 (HTLV-1), é fornecido um método de diagnóstico para uma doença relacionada ao HTLV-1 com base em uma quantidade de receptor 2 do fator de necrose tumoral (TNFR2) em uma amostra de sangue retirada de um indivíduo, em que (1) é determinado com base em um aumento da quantidade de TNFR2 que o indivíduo sofre, ou é provável que desenvolva, a doença relacionada ao HTLV-1; e/ou (2) é determinada com base em uma diminuição da quantidade de TNFR2 que o indivíduo está em remissão, ou é provável que esteja em remissão, da doença relacionada ao HTLV-1.
BR112022007705A 2019-11-05 2020-11-02 Método para diagnóstico de doença relacionada ao vírus da leucemia tipo 1 de células t humanas (htlv-1) BR112022007705A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019200986 2019-11-05
PCT/JP2020/041000 WO2021090786A1 (ja) 2019-11-05 2020-11-02 ヒトｔ細胞白血病ウイルス１型（ｈｔｌｖ－１）関連疾患の診断方法

Publications (1)

Publication Number Publication Date
BR112022007705A2 true BR112022007705A2 (pt) 2022-07-12

Family

ID=75848489

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007705A BR112022007705A2 (pt) 2019-11-05 2020-11-02 Método para diagnóstico de doença relacionada ao vírus da leucemia tipo 1 de células t humanas (htlv-1)

Country Status (7)

Country Link
US (1) US20220404363A1 (pt)
EP (1) EP4056587A4 (pt)
JP (1) JP7356650B2 (pt)
BR (1) BR112022007705A2 (pt)
TW (1) TW202124958A (pt)
WO (1) WO2021090786A1 (pt)
ZA (1) ZA202204902B (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3761861B2 (ja) * 2002-11-08 2006-03-29 弘 高橋 白血病の検出方法及びそのための試薬
JP4227881B2 (ja) 2003-11-13 2009-02-18 財団法人宮崎県産業支援財団 成人ｔ細胞白血病診断薬
JP2008292474A (ja) * 2007-04-27 2008-12-04 Nationa Hospital Organization 成人ｔ細胞白血病発症リスク判定方法
JP5522348B2 (ja) * 2008-03-19 2014-06-18 国立大学法人 岡山大学 成人ｔ細胞白血病・リンパ腫の予後推定法およびキット
JP6051594B2 (ja) * 2011-05-20 2016-12-27 国立大学法人 大分大学 糖質プロファイリングによる血液腫瘍診断のための診断基準を得る方法
JP2014059299A (ja) * 2012-08-24 2014-04-03 Nationa Hospital Organization 慢性型成人ヒトｔ細胞白血病（ａｔｌ）から急性型ａｔｌへの急性転化のし易さを試験する方法
JP6206953B2 (ja) * 2012-08-24 2017-10-04 独立行政法人国立病院機構 成人ｔ細胞白血病の発症し易さを試験する方法

Also Published As

Publication number Publication date
JP7356650B2 (ja) 2023-10-05
WO2021090786A1 (ja) 2021-05-14
EP4056587A4 (en) 2023-11-22
JPWO2021090786A1 (pt) 2021-05-14
US20220404363A1 (en) 2022-12-22
ZA202204902B (en) 2023-01-25
EP4056587A1 (en) 2022-09-14
TW202124958A (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
BR112017025297A2 (pt) anticorpos anti-gitr para diagnóstico do câncer
BR112022001383A2 (pt) Avaliação de saúde animal
BR112018010269A2 (pt) mr-proadm como marcador para o status do volume extracelular de um indivíduo
BR112017007962A2 (pt) método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
MX362514B (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
BR112018000749A2 (pt) métodos e composições para a diagnose e para o tratamento de adrenoleucodistrofia
SI2925888T1 (en) Compounds and methods for the treatment of cancer
BR112015018213A8 (pt) métodos para determinar a síndrome da angústia respiratória aguda (ards) e para monitorar o desenvolvimento desta e kit para diagnóstico".
BR112017017076A2 (pt) inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre.
BR112017014419A2 (pt) diagnose e tratamento de diabetes incipiente
BR112018008462A2 (pt) aparelho para avaliação do desempenho em serviços de saúde e mídia de armazenamento não transitório
BR112018002550A2 (pt) mecanismo de resistência a inibidores do bromodomínio de bet
BR112018075961A2 (pt) sistemas de diagnóstico baseados em imagem
AR088244A1 (es) oxMIF COMO MARCADOR DE DIAGNOSTICO
Shahid et al. Fatigue severity scale (FSS)
BR112015027249A2 (pt) método de diagnóstico de câncer
BR112022007705A2 (pt) Método para diagnóstico de doença relacionada ao vírus da leucemia tipo 1 de células t humanas (htlv-1)
Gün et al. Multidetector angio-CT and the use of D-dimer for the diagnosis of acute mesenteric ischemia in geriatric patients
AU2011291450A8 (en) TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease
Widyaningsih et al. The quality of life of Indonesian patients with advanced cancer
ES2723797A1 (es) Determinación de alteraciones en la metilación del gen ANKYRIN REPEAT-AND SOCS BOX - CONTAINNG PROTEIN 1, como marcador de disfunción ventricular y del volumen latido del ventrículo izquierdo en pacientes con cardiopatías isquémica
UA117186C2 (uk) Спосіб діагностики рецидиву захворювання у хворих на рак ободової кишки
UA122583U (uk) Спосіб діагностики та лікування аномалій положення оклюзійної площини
RU2014114573A (ru) Способ определения метода обследования пациентов с хронической обструктивной болезнью легких
RU2013141486A (ru) Способ определения результативности лечения больных